1. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
- Author
-
Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, and McDonald DM
- Subjects
- Actins metabolism, Angiogenesis Inhibitors pharmacology, Animals, Antibodies, Monoclonal pharmacology, Axitinib, Basement Membrane drug effects, Basement Membrane metabolism, Basement Membrane pathology, Blood Vessels drug effects, Blood Vessels metabolism, Blood Vessels pathology, Carcinoma, Lewis Lung blood supply, Carcinoma, Lewis Lung pathology, Collagen Type IV immunology, Collagen Type IV metabolism, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Endothelium, Vascular pathology, Imidazoles pharmacology, Imidazoles therapeutic use, Indazoles pharmacology, Indazoles therapeutic use, Insulinoma blood supply, Insulinoma pathology, Matrix Metalloproteinase Inhibitors, Mice, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms blood supply, Neoplasms drug therapy, Neoplasms pathology, Neovascularization, Pathologic metabolism, Neovascularization, Pathologic pathology, Organic Chemicals pharmacology, Pericytes drug effects, Pericytes metabolism, Pericytes pathology, Platelet Endothelial Cell Adhesion Molecule-1 metabolism, Receptor, Platelet-Derived Growth Factor beta metabolism, Treatment Outcome, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors, Vascular Endothelial Growth Factor Receptor-2 metabolism, Angiogenesis Inhibitors therapeutic use, Carcinoma, Lewis Lung drug therapy, Insulinoma drug therapy, Neovascularization, Pathologic drug therapy, Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors
- Abstract
Inhibitors of VEGF signaling can block angiogenesis and reduce tumor vascularity, but little is known about the reversibility of these changes after treatment ends. In the present study, regrowth of blood vessels in spontaneous RIP-Tag2 tumors and implanted Lewis lung carcinomas in mice was assessed after inhibition of VEGF receptor signaling by AG-013736 or AG-028262 for 7 days. Both agents caused loss of 50%-60% of tumor vasculature. Empty sleeves of basement membrane were left behind. Pericytes also survived but had less alpha-SMA immunoreactivity. One day after drug withdrawal, endothelial sprouts grew into empty sleeves of basement membrane. Vessel patency and connection to the bloodstream followed close behind. By 7 days, tumors were fully revascularized, and the pericyte phenotype returned to baseline. Importantly, the regrown vasculature regressed as much during a second treatment as it did in the first. Inhibition of MMPs or targeting of type IV collagen cryptic sites by antibody HUIV26 did not eliminate the sleeves or slow revascularization. These results suggest that empty sleeves of basement membrane and accompanying pericytes provide a scaffold for rapid revascularization of tumors after removal of anti-VEGF therapy and highlight their importance as potential targets in cancer therapy.
- Published
- 2006
- Full Text
- View/download PDF